

KRYSTAL-7: A Phase 2 Trial of Adagrasib (MRTX849) With Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) With KRAS^{G12C} Mutation

Alexander I. Spira¹, William E. Lawler², Merrill Shum³, Mark A. Socinski⁴, Ronald Yanagihara⁵, Sahar Roshan⁶, Thian Kheoh⁶, James G. Christensen⁶, Richard C. Chao⁶, Pasi A. Jänne⁷, Marina Garassino⁸.

¹Virginia Cancer Specialists, Fairfax, VA, USA; ²US Oncology Research, The Woodlands, TX, USA; ³Virginia K. Crosson Cancer Center, Fullerton, CA, USA; ⁴The Oncology Institute, Whittier, CA, USA; ⁵Thoracic Oncology Program, AdventHealth Cancer Institute, Orlando, FL, USA; ⁶Straub Medical Center, Honolulu, HI, USA; ⁷Mirati Therapeutics, Inc., San Diego, CA, USA; ⁸Dana-Farber Cancer Institute, Boston, MA, USA; ⁹Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Background

KRAS-Driven NSCLC

- KRAS^{G12C} mutations act as oncogenic drivers and occur in approximately 14% of NSCLC (adenocarcinomas)¹⁻³
- Mutations in codon 12 of KRAS are associated with a poor prognosis, and although KRAS has historically been undruggable, KRAS^{G12C} can now be inhibited covalently^{4,5}
- Emerging data demonstrate clinical activity of KRAS^{G12C} inhibitors in pretreated patients with NSCLC harboring KRAS^{G12C} mutations⁶

Adagrasib in KRAS^{G12C} Cancers

- Adagrasib is a covalent inhibitor of KRAS^{G12C} that irreversibly and selectively binds KRAS^{G12C} and locks it in its inactive, GDP-bound state⁶ (Figure 1)
- Adagrasib inhibits KRAS^{G12C} mediated MAP/ERK signaling and tumor growth
- Adagrasib was optimized for desired properties of a KRAS^{G12C} inhibitor:
 - Potent covalent inhibition of KRAS^{G12C} (cellular IC₅₀: ~5 nM)
 - High selectivity (>1000X) for the mutant KRAS^{G12C} protein vs wild-type (WT) KRAS
 - Favorable PK properties, including oral bioavailability, long half-life (~24 h), and extensive tissue distribution⁶
- Initial results from KRYSTAL-1, a Phase 1/2 study, demonstrated antitumor activity and tolerability of adagrasib monotherapy across multiple tumor types harboring KRAS^{G12C} mutation, including patients with NSCLC previously treated with both platinum-based chemotherapy and immune checkpoint inhibitors⁶ (Figure 2)
- In a safety analysis of patients (n=110) from KRYSTAL-1, adagrasib was well tolerated, with few grade 3-4 treatment-related AEs (TRAEs)⁶
 - The most common TRAEs included nausea, diarrhea, vomiting, and fatigue

Figure 1: Mechanism of Action (MOA) of Adagrasib





Figure 2. Adagrasib 600 mg BID in Patients With Pretreated NSCLC (KRYSTAL-1)⁶



- 45% (23/51) of patients with NSCLC had a confirmed ORR
- 51% (26/51) of patients with NSCLC achieved SD
- Clinical benefit (DCR) was observed in 96.1% (49/51) of patients

Data as of 30 August 2020. Pooled data includes patients with NSCLC who received adagrasib 600 mg BID in Phase 1/1b and Phase 2

Combination With Immune Checkpoint Inhibition


Synergy Between KRAS^{G12C} Inhibition and Immune Checkpoint Inhibition

- KRAS^{G12C} mutations are smoking-related transversion mutations associated with a relatively high tumor mutational burden (TMB) and PD-L1 positivity^{7,8}
- Data suggest synergy between KRAS^{G12C} inhibition and immune checkpoint inhibition (CPI)⁹
- Adagrasib treatment alters tumor expression of factors implicated in the presentation of tumor antigens and/or mediates an immunosuppressive tumor microenvironment in multiple KRAS^{G12C} xenografts⁹
- These data support the rationale to further evaluate adagrasib in combination with CPIs in patients with first-line advanced/metastatic NSCLC
- The adagrasib + pembrolizumab combination (NSCLC) arm in KRYSTAL-1 has cleared the DLT observation period¹⁰

KRAS^{G12C} Syngeneic Mouse Model

- Adagrasib plus anti-PD-1 therapy led to durable complete responses (DCRs; cures) in the majority of mice and a survival advantage relative to either agent as monotherapy⁷ (Figure 3)
- In mouse models showing complete response, reintroduction of tumor cell inoculum failed to result in re-formation of tumor, demonstrating durable antitumor immunity for the combination⁷⁻⁹

Figure 3. Preclinical Data Demonstrating Survival in a KRAS^{G12C} Syngeneic Mouse Model



Methods

Key Inclusion Criteria

- Aged 18 years or older and Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Histologically confirmed diagnosis of NSCLC with KRAS^{G12C} mutation and known PD-L1 tumor proportion score (TPS)
- Unresectable or metastatic disease (ie, not a candidate for definitive therapy such as chemoradiation for locally advanced disease)
- Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1
- Expected availability of representative tumor specimen (fresh or archived) for central laboratory testing of correlative gene alterations

Key Exclusion Criteria

- Prior systemic treatment for locally advanced or metastatic NSCLC, including chemotherapy, CPI therapy, or a therapy targeting KRAS^{G12C} mutation
- Active brain metastases; patients are eligible if brain metastases are adequately treated and patients are neurologically stable for at least 2 weeks prior to the first dose of study treatment without the use of corticosteroids or are on a stable or decreasing dose of ≤10 mg daily prednisone (or equivalent)

Testing Procedures

Testing for PD-L1 Expression


- Molecular testing for PD-L1 TPS should be performed centrally or locally using a sponsor-approved test and laboratory prior to or during the prescreening period
- Tumor tissue samples should be collected from the most recent biopsy or excision, preferably no more than 6 months earlier and without prior systemic treatment or radiation to the site of tissue collection

Detection of KRAS^{G12C} Mutation for Trial Eligibility

- The presence of KRAS^{G12C} mutation established using sponsor-approved methods and laboratories:
 - In tumor tissue, including polymerase chain reaction (PCR) and next-generation sequencing (NGS) platforms
 - In blood samples, for circulating tumor deoxyribonucleic acid (ctDNA) analysis, including NGS platforms

Methods

Figure 4. KRYSTAL-7 Study Design



BID, twice daily; IV, intravenously; NSCLC, non-small-cell lung cancer; Q3W, every 3 weeks; TPS, tumor proportion score.

Study Design

- KRYSTAL-7 (849-007) is a global, open-label, Phase 2 study evaluating the clinical activity of adagrasib administered in combination with pembrolizumab as treatment for patients with advanced NSCLC harboring a KRAS^{G12C} mutation
- An estimated 120 patients will be enrolled into 2 cohorts based on PD-L1 TPS: Cohort A (TPS <1%) and Cohort B (TPS ≥1%) (Figure 4)
- Patients will receive study treatment until disease progression, unacceptable tolerability, or investigator decision to terminate treatment
- This study was initiated November 2020

Study Treatments

- Adagrasib is to be dosed at 600 mg (BID) in 3-week cycles administered orally on a continuous basis until disease progression
- Pembrolizumab is to be dosed at 200 mg every 3 weeks (Q3W); if permitted by local labeling, after 9 months or more on study treatment, individual patients may switch to 400 mg administered every 6 weeks (Q6W), at the investigator's discretion
 - Pembrolizumab treatment may continue for up to 24 months or in accordance with approved local labeling

Primary Endpoint

- Objective response rate (ORR), as defined by RECIST 1.1

Secondary Endpoints

- Safety, including adverse events and laboratory abnormalities
- PK, including blood plasma levels of adagrasib and potential metabolite concentrations
- Secondary efficacy endpoints:
 - Duration of response (DOR)
 - Progression-free survival (PFS)
 - 1-Year survival rate
 - Overall survival (OS)

Exploratory Endpoints

- Proportion of selected cell populations (including subpopulations of T-cells and myeloid cells) in the blood before and after study treatment
- T-cell receptor repertoire in the blood before and after study treatment
- Gene alterations in tumor tissue and ctDNA before treatment and at disease progression


Statistical Methods

Simon's Optimal 2-Stage Design¹¹

- Simon's optimal two-stage design will be used to calculate the sample size for each Phase 2 cohort
- The number of responses in the first stage of each Phase 2 cohort will be assessed for potential early study termination

Trial Progress

- Approximately 40 global sites are planned for this study
- Enrollment is currently ongoing at sites from the United States, Canada, Italy, the Netherlands, and Spain



Summary

- Adagrasib is a KRAS^{G12C}-selective covalent inhibitor with a long half-life and extensive predicted target coverage throughout the dosing interval⁶
- The adagrasib + pembrolizumab combination (NSCLC) arm in KRYSTAL-1 has cleared the DLT observation period
- KRYSTAL-7 is a global, open-label Phase 2 study designed to further evaluate the clinical activity of adagrasib in combination with pembrolizumab administered as first-line treatment for patients with advanced NSCLC harboring a KRAS^{G12C} mutation
- ClinicalTrials.gov identifier: NCT04613596

References

1. Zehir A, et al. *Nat Med*. 2017;23(6):703-713.
2. Schirripa M, et al. *Clin Colorectal Cancer*. 2020;S1533-0028(20)30067-0.
3. The Cancer Genome Atlas. National Cancer Institute GDC Data Portal. Accessed on December 1, 2020. <https://portal.gdc.cancer.gov/>
4. Christensen JG, et al. *J Intern Med*. 2020; 288:183-191
5. Hu Q, Shokat KM. *Cell*. 2018;173(5):1254-1264.
6. Jänne PA, et al. KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/Metastatic Non-Small-Cell Lung Cancer (NSCLC) Harboring KRAS^{G12C} Mutation. Oral presentation at 2020 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 25, 2020; virtual.
7. Campbell JD, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. *Nat Genet*. 2019;48(6):607-616.
8. Goodman AM, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. *Mol Cancer Ther*. 2017;16(11):2598-2600.
9. Briere D, et al. The KRAS^{G12C} inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model. Poster presented at: 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA.
10. Ferrer I, et al. KRAS Mutant non-small cell lung cancer: From biology to therapy. *Lung Cancer*. 2018;124:53-64.
11. Simon R. *Controlled Clinical Trials*. 1989;10:1-10.

Acknowledgments

- The patients and their families who make this trial possible
- The clinical study teams for their work and contributions
- This study is supported by Mirati Therapeutics, Inc.
- All authors contributed to and approved this presentation; writing and editorial assistance were provided by Andrew Hong of Axiom Healthcare Strategies, funded by Mirati Therapeutics, Inc.

Copies of this poster can be obtained through Quick Response (QR). Copies are for personal use only and may not be reproduced without permission from WCLC® and the authors of this poster.

